Direct Percutaneous Gene Delivery to Enhance Healing of Segmental Bone Defects
- 1 February 2006
- journal article
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 88 (2) , 355-365
- https://doi.org/10.2106/jbjs.e.00464
Abstract
Healing of segmental bone defects can be induced experimentally with genetically modified osteoprogenitor cells, an ex vivo strategy that requires two operative interventions and substantial cost. Direct transfer of osteogenic genes offers an alternative, clinically expeditious, cost-effective approach. We evaluated its potential in a well-established, critical-size, rat femoral defect model. A critical-size defect was created in the right femur of forty-eight skeletally mature Sprague-Dawley rats. After twenty-four hours, each defect received a single, intralesional, percutaneous injection of adenovirus carrying bone morphogenetic protein-2 (Ad.BMP-2) or luciferase cDNA (Ad.luc) or it remained untreated. Healing was monitored with weekly radiographs. At eight weeks, the rats were killed and the femora were evaluated with dual-energy x-ray absorptiometry, micro-computed tomography, histological analysis, histomorphometry, and torsional mechanical testing. Radiographically, 75% of the Ad.BMP-2-treated femora showed osseous union. Bone mineral content was similar between the Ad.BMP-2-treated femora (0.045 +/- 0.020 g) and the contralateral, intact femora (0.047 +/- 0.003 g). Histologically, 50% of the Ad.BMP-2-treated defects were bridged by lamellar, trabecular bone; the other 50% contained islands of cartilage. The control (Ad.luc-treated) defects were filled with fibrous tissue. Histomorphometry demonstrated a large difference in osteogenesis between the Ad.BMP-2 group (mean bone area, 3.25 +/- 0.67 mm(2)) and the controls (mean bone area, 0.65 +/- 0.67 mm(2)). By eight weeks, the Ad.BMP-2-treated femora had approximately one-fourth of the strength (mean, 0.07 +/- 0.04 Nm) and stiffness (mean, 0.5 +/- 0.4 Nm/rad) of the contralateral femora (0.3 +/- 0.08 Nm and 2.0 +/- 0.5 Nm/rad, respectively). A single, percutaneous, intralesional injection of Ad.BMP-2 induces healing of critical-size femoral bone defects in rats within eight weeks. At this time, the repair tissue is predominantly trabecular bone, has normal bone mineral content, and has gained mechanical strength.Keywords
This publication has 34 references indexed in Scilit:
- Bone Morphogenetic ProteinsGrowth Factors, 2004
- Gene Transfer Approaches to the Healing of Bone and CartilageMolecular Therapy, 2002
- THE ROLE OF GROWTH FACTORS IN THE REPAIR OF BONEJournal of Bone and Joint Surgery, 2002
- Effects of carrier release kinetics on bone morphogenetic protein‐2‐induced periodontal regeneration in vivoJournal of Clinical Periodontology, 2001
- Factors Affecting Nonunion of the Allograft-Host JunctionClinical Orthopaedics and Related Research, 2001
- A Prospective Comparison of Surgical Approach for Anterior L4–L5 FusionSpine, 2000
- Complications of Irradiated Allografts in Orthopaedic Tumor SurgeryPublished by Wolters Kluwer Health ,2000
- Bone Morphogenetic Proteins: From Basic Studies to Clinical ApproachesBone, 1998
- Complications of Iliac Crest Bone Graft HarvestingClinical Orthopaedics and Related Research, 1996
- The Incidence of Osteitis in Open Fractures: An Analysis of 948 Open Fractures (A Review of the Hannover Experience)Journal of Orthopaedic Trauma, 1993